News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2023 RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1 Caitlin E. Cox November 11, 2023
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News AHA 2020 Black, Hispanic Individuals Bear Pandemic’s Brunt: AHA COVID-19 CVD Registry Todd Neale November 18, 2020
News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017
News Conference News AHA 2016 Secondhand Smoke Exposure Associated With Increased Risk of Coronary Atherosclerosis Michael O'Riordan November 13, 2016
News Conference News AHA 2016 No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION Shelley Wood November 13, 2016